Interferon alpha-n1 - Dainippon Sumitomo Pharma

Drug Profile

Interferon alpha-n1 - Dainippon Sumitomo Pharma

Alternative Names: IFN-α - Dainippon Sumitomo Pharma; Interferon-alfa - Dainippon Sumitomo Pharma; Interferon-α NAMALWA; Sumiferon

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Sumitomo Dainippon Pharma
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cirrhosis

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 31 Oct 2008 Registered for compensated Cirrhosis associated with chronic hepatitis C in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top